Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin: A Pharmacokinetic-Based Management Approach
{{output}}
Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) approved for metastatic urothelial carcinoma, is increasingly recognized to cause severe hyperglycemia and diabetic ketoacidosis (DKA). However, optimal management of EV-associated refractory DKA remain... ...
